Clinical trial · Observational
Biomarkers and Molecular Mechanism Study of Hepatocellular Carcinoma After Radical Resection and Conversion Therapy
NCT06382103CI-TRIAL-00087701recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Blood samples will be tested to identify circulating tumor DNA and plasma protein levels to potentially improve prediction of long term prognosis and guide treatment options of patients with hepatocellular carcinoma underwent surgical resection.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ctDNA monitoring | Diagnostic Test | — | UNRESOLVED |
| Plasma proteomic analysis | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Correlation between ctDNA level and recurrence-free survival (RFS)
- timeFrame
- 1 years
- description
- ctDNA measurements will be made at baseline and 1 months, 3 months, 6 months, 12 months after surgery. RFS will be assessed by standard radiographic imaging.
- measure
- Correlation between specific plasma protein expression level and recurrence-free survival (RFS)
- timeFrame
- 1 years
- description
- plasma proteomic measurements will be made at baseline and 1 months, 3 months, 6 months, 12 months after surgery. RFS will be assessed by standard radiographic imaging.
Secondary outcomes (1)
- measure
- Correlation between tumor mutation numbers and recurrence-free survival (RFS)
- timeFrame
- 1 years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Patients with a first diagnosis of HCC. * Patients with HCC who are to undergo surgical treatment, with or without neoadjuvant therapy. * Ability to obtain tissue sample for ctDNA analysis and detectable baseline ctDNA level. Exclusion Criteria: * Patients with secondary liver cancer, or intrahepatic cholangiocarcinoma. * Any other concurrent malignancy. * History of organ transplant or hepatic encephalopathy.
References
Publications (0)
Data not yet available
No reference posted for this study.